

FEDERAL RESERVE SYSTEM**Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities**

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than November 10, 2005.

A. Federal Reserve Bank of Atlanta
(Andre Anderson, Vice President) 1000 Peachtree Street, N.E., Atlanta, Georgia 30303:

1. *Chestatee Bancshares, Inc.*, Dawsonville, Georgia, to continue to engage through Chestatee Financial Services, Inc., Dawsonville, Georgia, in securities brokerage activities and the sale of insurance in a town of less than 5,000 persons, pursuant to sections 225.28(b)(7)(i) and 225.28(b)(11)(iii)(A) of Regulation Y.

Board of Governors of the Federal Reserve System, October 21, 2005.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. E5-5955 Filed 10-25-05; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RESERVE SYSTEM**Sunshine Act Meeting**

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 12 p.m., Monday, October 31, 2005.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW., Washington, DC 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

FOR FURTHER INFORMATION CONTACT:

Michelle A. Smith, Director, Office of Board Members; 202-452-2955.

SUPPLEMENTARY INFORMATION: You may call 202-452-3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at <http://www.federalreserve.gov> for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Board of Governors of the Federal Reserve System, October 21, 2005.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 05-21419 Filed 10-21-05; 4:16pm]

BILLING CODE 6210-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Office of the Secretary**

[Document Identifier: OS-0990-0263]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Office of the Secretary, HHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any

of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

#1 Type of Information Collection Request: Extension of Currently Approved Collection;

Title of Information Collection: Protection of Human Subjects Assurance Identification/ Institutional Review Board (IRB) Certification/ Declaration of Exemption;

Form/OMB No.: OS-0990-0263;

Use: The Federal Policy for the Protection of Human Subjects, known as the Common Rule, requires that before engaging in non-exempt human subjects research that is conducted or supported by a Common Rule department or agency, each institution must: (1) Hold an applicable assurance of compliance [Section 103(a)]; and (2) certify to the awarding department or agency that the application or proposal for research has been reviewed and approved by an IRB designated in the assurance [Sections 103(b) and (f)].

Frequency: Reporting on occasion;

Affected Public: Federal, State, local, or tribal governments, business or other for-profit, not-for-profit institutions and individuals or households;

Annual Number of Respondents: 5,000;

Total Annual Responses: 166,667;

Average Burden Per Response: 0.25 hours;

Total Annual Hours: 41,667;

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access the HHS Web site address at <http://www.hhs.gov/oirm/infocollect/pending/> or e-mail your request, including your address, phone number, OMB number, and OS document identifier, to naomi.cook@hhs.gov, or call the Reports Clearance Office on (202) 690-6162.

Written comments and recommendations for the proposed information collections must be mailed within 30 days of this notice directly to the Desk Officer at the address below: OMB Desk Officer: John Kraemer, OMB Human Resources and Housing Branch, Attention: (OMB #0990-0263), New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: October 17, 2005.

Robert E. Polson,

Office of the Secretary, Paperwork Reduction Act Reports Clearance Officer.

[FR Doc. 05-21356 Filed 10-25-05; 8:45 am]

BILLING CODE 4168-17-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel; Meeting

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Enhancing Utilization of Childhood Immunization Client Recall Practices by Private Providers, RFA; IP 05-088; Improving Vaccination Coverage in the Greater than 65 Years of Age Population, RFA IP 05-091; Influenza Vaccination of Children and Accompanying Adults: Mass Vaccination versus Vaccination in Routine Care, RFA IP 05-094; Effectiveness of a Hospital Based Program for Vaccination of Birth Mothers and Household Contacts with Inactivated Influenza Vaccine, RFA; IP 05-095; and Developing Methods and Strategies to Increase Use of Immunization Registries by Private Providers, RFA IP 05-096.

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Enhancing Utilization of Childhood Immunization Client Recall Practices by Private Providers, RFA IP 05-088; Improving Vaccination Coverage in the Greater than 65 Years of Age Population, RFA IP 05-091; Influenza Vaccination of Children and Accompanying Adults: Mass Vaccination versus Vaccination in Routine Care, RFA IP 05-094; Effectiveness of a Hospital Based Program for Vaccination of Birth Mothers and Household Contacts with Inactivated Influenza Vaccine, RFA IP 05-095; and Developing Methods and Strategies to Increase Use of Immunization Registries by Private Providers, RFA IP 05-096.

Times and Dates: 8 a.m.-5 p.m., November 21, 2005 (Closed).

Place: Renaissance Hotel, 1 Hartsfield Center Parkway, Atlanta, GA 30354, Telephone 404.209.9999.

Status: The meeting will be closed to the public in accordance with

provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Enhancing Utilization of Childhood Immunization Client Recall Practices by Private Providers, RFA IP 05-088; Improving Vaccination Coverage in the Greater than 65 Years of Age Population, RFA IP 05-091; Influenza Vaccination of Children and Accompanying Adults: Mass Vaccination versus Vaccination in Routine Care, RFA IP 05-094; Effectiveness of a Hospital Based Program for Vaccination of Birth Mothers and Household Contacts with Inactivated Influenza Vaccine, RFA IP 05-095; and Developing Methods and Strategies to Increase Use of Immunization Registries by Private Providers, RFA IP 05-096.

FOR FURTHER INFORMATION CONTACT: Horace M. Stiles, PHD MPH DDS, Scientific Review Administrator, National Institute for Occupational Safety and Health, CDC, 1600 Clifton Road, NE., MS E-74, Atlanta, GA 30333, Telephone 404-498-2584.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: October 19, 2005.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 05-21341 Filed 10-25-05; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Vaccines and Related Biological Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on November 16, 2005, from 8:30 a.m. to 5:15 p.m. and on November 17, 2005, from 8:30 a.m. to 5:30 p.m.

Location: Holiday Inn Select, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Christine Walsh or Denise Royster, Center for Biologics Evaluation and Research (HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512391. Please call the Information Line for up-to-date information on this meeting.

Agenda: On November 16, 2005, the committee will hear presentations and discuss the use of Madin-Darby Canine Kidney Cells for manufacture of Inactivated Influenza Vaccines. On November 17, 2005, the committee will discuss developing new Pneumococcal Vaccines for U.S. licensure for adults.

Procedure: On November 16, 2005, from 8:30 a.m. to 5:15 p.m. and on November 17, 2005, from 10 a.m. to 5:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by November 9, 2005. Oral presentations from the public will be scheduled on November 16, 2005, between approximately 1:45 p.m. and 2:15 p.m. and on November 17, 2005, between approximately 1 p.m. and 1:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 9, 2005, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On November 17, 2005, from 8:30 a.m. to 9:55 a.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)).

Persons attending FDA's advisory committee meetings are advised that the